Ball & Co Wealth Management Inc. Takes $677,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Ball & Co Wealth Management Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 7,335 shares of the biopharmaceutical company's stock, valued at approximately $677,000. Gilead Sciences makes up 0.5% of Ball & Co Wealth Management Inc.'s portfolio, making the stock its 12th largest holding.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Toronto Dominion Bank lifted its position in Gilead Sciences by 11.0% during the 4th quarter. Toronto Dominion Bank now owns 710,523 shares of the biopharmaceutical company's stock worth $65,631,000 after buying an additional 70,551 shares in the last quarter. Formidable Asset Management LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $212,000. North Star Asset Management Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $201,000. Cache Advisors LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $1,008,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $26,266,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 2.2%

Shares of Gilead Sciences stock traded up $2.43 on Thursday, reaching $110.87. The company's stock had a trading volume of 2,339,375 shares, compared to its average volume of 7,701,747. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The firm's fifty day simple moving average is $105.36 and its two-hundred day simple moving average is $100.57. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $137.91 billion, a price-to-earnings ratio of 299.18, a P/E/G ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm's quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.32) earnings per share. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is presently 66.53%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GILD. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their price target for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Finally, The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,929 shares of company stock valued at $5,644,780. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.